618 related articles for article (PubMed ID: 10888650)
1. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
Nyambi PN; Mbah HA; Burda S; Williams C; Gorny MK; Nádas A; Zolla-Pazner S
J Virol; 2000 Aug; 74(15):7096-107. PubMed ID: 10888650
[TBL] [Abstract][Full Text] [Related]
2. A virus binding assay for studying the antigenic landscape on intact, native, primary human immunodeficiency virus-type 1.
Nyambi PN; Burda S; Bastiani L; Williams C
J Immunol Methods; 2001 Jul; 253(1-2):253-62. PubMed ID: 11384686
[TBL] [Abstract][Full Text] [Related]
3. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.
Nyambi PN; Gorny MK; Bastiani L; van der Groen G; Williams C; Zolla-Pazner S
J Virol; 1998 Nov; 72(11):9384-91. PubMed ID: 9765494
[TBL] [Abstract][Full Text] [Related]
4. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
5. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
[TBL] [Abstract][Full Text] [Related]
6. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
Gorny MK; Revesz K; Williams C; Volsky B; Louder MK; Anyangwe CA; Krachmarov C; Kayman SC; Pinter A; Nadas A; Nyambi PN; Mascola JR; Zolla-Pazner S
J Virol; 2004 Mar; 78(5):2394-404. PubMed ID: 14963135
[TBL] [Abstract][Full Text] [Related]
7. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.
Moore JP; Sattentau QJ; Wyatt R; Sodroski J
J Virol; 1994 Jan; 68(1):469-84. PubMed ID: 7504741
[TBL] [Abstract][Full Text] [Related]
8. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
McCaffrey RA; Saunders C; Hensel M; Stamatatos L
J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
[TBL] [Abstract][Full Text] [Related]
9. Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.
Nyambi PN; Nádas A; Mbah HA; Burda S; Williams C; Gorny MK; Zolla-Pazner S
J Virol; 2000 Nov; 74(22):10670-80. PubMed ID: 11044111
[TBL] [Abstract][Full Text] [Related]
10. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
[TBL] [Abstract][Full Text] [Related]
11. Antigenic properties of the HIV envelope on virions in solution.
Ray K; Mengistu M; Yu L; Lewis GK; Lakowicz JR; DeVico AL
J Virol; 2014 Feb; 88(3):1795-808. PubMed ID: 24284318
[TBL] [Abstract][Full Text] [Related]
12. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies.
Laal S; Burda S; Gorny MK; Karwowska S; Buchbinder A; Zolla-Pazner S
J Virol; 1994 Jun; 68(6):4001-8. PubMed ID: 7514683
[TBL] [Abstract][Full Text] [Related]
13. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
14. Defining human immunodeficiency virus (HIV) type 1 immunotypes with six human monoclonal antibodies.
Nádas A; Zhong P; Burda S; Zekeng L; Urbanski M; Gorny MK; Zolla-Pazner S; Nyambi PN
AIDS Res Hum Retroviruses; 2004 Jan; 20(1):55-65. PubMed ID: 15000699
[TBL] [Abstract][Full Text] [Related]
15. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
[TBL] [Abstract][Full Text] [Related]
16. Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.
Gohain N; Tolbert WD; Acharya P; Yu L; Liu T; Zhao P; Orlandi C; Visciano ML; Kamin-Lewis R; Sajadi MM; Martin L; Robinson JE; Kwong PD; DeVico AL; Ray K; Lewis GK; Pazgier M
J Virol; 2015 Sep; 89(17):8840-54. PubMed ID: 26085162
[TBL] [Abstract][Full Text] [Related]
17. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities.
Alsmadi O; Tilley SA
J Virol; 1998 Jan; 72(1):286-93. PubMed ID: 9420226
[TBL] [Abstract][Full Text] [Related]
18. Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.
Upadhyay C; Mayr LM; Zhang J; Kumar R; Gorny MK; Nádas A; Zolla-Pazner S; Hioe CE
J Virol; 2014 Nov; 88(21):12853-65. PubMed ID: 25165106
[TBL] [Abstract][Full Text] [Related]
19. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner.
Musich T; Li L; Liu L; Zolla-Pazner S; Robert-Guroff M; Gorny MK
J Virol; 2017 Apr; 91(8):. PubMed ID: 28122974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
